Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Inventory: 2011-2025

Historic Inventory for Myriad Genetics (MYGN) over the last 14 years, with Sep 2025 value amounting to $31.6 million.

  • Myriad Genetics' Inventory rose 20.61% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.6 million, marking a year-over-year increase of 20.61%. This contributed to the annual value of $27.5 million for FY2024, which is 25.00% up from last year.
  • Myriad Genetics' Inventory amounted to $31.6 million in Q3 2025, which was up 10.10% from $28.7 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Inventory high stood at $31.6 million for Q3 2025, and its period low was $15.3 million during Q4 2021.
  • Moreover, its 3-year median value for Inventory was $26.1 million (2024), whereas its average is $25.9 million.
  • As far as peak fluctuations go, Myriad Genetics' Inventory plummeted by 43.54% in 2021, and later skyrocketed by 46.10% in 2023.
  • Quarterly analysis of 5 years shows Myriad Genetics' Inventory stood at $15.3 million in 2021, then spiked by 31.37% to $20.1 million in 2022, then rose by 9.45% to $22.0 million in 2023, then climbed by 25.00% to $27.5 million in 2024, then rose by 20.61% to $31.6 million in 2025.
  • Its last three reported values are $31.6 million in Q3 2025, $28.7 million for Q2 2025, and $28.3 million during Q1 2025.